Janux Therapeutics, Inc. beat EPS estimates 75% of the time across 16 reported quarters (12 beats, 4 misses), averaging +11.2% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.26 | $-0.35 | -34.6% | Miss | |
| Q1 FY26 | $-0.50 | $-0.39 | +22.0% | Beat | |
| Q4 FY25 | $-0.65 | $-0.51 | +21.5% | Beat | |
| Q3 FY25 | $-0.60 | $-0.39 | +35.0% | Beat | |
| Q2 FY25 | $-0.48 | $-0.55 | -14.6% | Miss | |
| Q1 FY25 | $-0.43 | $-0.38 | +11.6% | Beat | |
| Q4 FY24 | $-0.49 | $-0.36 | +26.5% | Beat | |
| Q3 FY24 | $-0.37 | $-0.51 | -37.8% | Miss | |
| Q2 FY24 | not reported | $-0.11 | not reported | not reported | |
| Q1 FY24 | $-0.35 | $-0.30 | +14.3% | Beat | |
| Q4 FY23 | $-0.37 | $-0.25 | +32.4% | Beat | |
| Q3 FY23 | $-0.46 | $-0.25 | +45.6% | Beat |
Back to JANX overview · JANX holders · JANX KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.